title: Penile rehabilitation with phosphodiesterase type 5 inhibitors after nerve-sparing radical prostatectomy: are we targeting the right patients?
abstract: The results reported in all trials comparing chronic versus on-demand phosphodiesterase type 5 inhibitor use after bilateral nerve-sparing radical prostatectomy may be affected by improper patient selection. Targeting the right patients is the key to optimizing the efficacy of these drugs.
authors.affiliation: San Raffaele Scientific Institute, Urological Research Institute, Milan, Italy.
authors.forename: Fabio
authors.initials: F
authors.lastname: Castiglione
authors.affiliation: San Raffaele Scientific Institute, Urological Research Institute, Milan, Italy.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Nini
authors.affiliation: San Raffaele Scientific Institute, Urological Research Institute, Milan, Italy. Electronic address: briganti.alberto@hsr.it.
authors.forename: Alberto
authors.initials: A
authors.lastname: Briganti
mesh_terms: D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000534:rehabilitation*; D006801:Humans; D008297:Male; D059351:Organ Sparing Treatments; D018579:Patient Selection; D010413:Penis / Q000294:innervation; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use*; D011468:Prostatectomy / Q000009:adverse effects* / Q000379:methods*
chemical_list: D058986:Phosphodiesterase 5 Inhibitors